KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Now Trending: Simplified HIV Treatments, Lesser-Known Social Detriments of Health September 7, 2024Check out this recap of articles published on our sister sites during the past week.
- Small Doses: September 2 to September 6 September 7, 2024Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
- Abbott’s OTC Lingo CGM for Wellness Now Available September 6, 2024Lingo offers users a real-time glucose graph, a metric to track glucose spikes, food and activity logging, personal recommendations, and challenges to motivate healthy behaviors.
- Community Pharmacist-Led Intervention for Victims of Domestic Abuse, Suicidal Ideation September 6, 2024Researchers analyzed a co-developed pharmacy-based intervention for individuals who have experienced domestic abuse or suicidal ideation.
- FDA Approves Nymalize in Prefilled ENFit Syringes September 6, 2024Nymalize is an effective alternative to capsule extraction for adult patients with subarachnoid hemorrhage who are unable to swallow capsules.
- A Total View of Central Fulfillment Strategies September 6, 2024Transform your pharmacy operations with centralized fulfillment. This whitepaper reveals how advanced automation can help you manage rising prescription volumes and workforce challenges. Learn how leading pharmacies optimize efficiency and reduce costs with proprietary software and automated robotic solutions. Download now and discover the future of pharmacy fulfillment.
- FDA Roundup: Novavax COVID-19 Vaccine, First Digital Therapeutic for GAD September 6, 2024Check out important updates from the FDA for the week of September 2.
- NCPA Calls on CMS to Establish PBM Protection for Independent Pharmacies September 5, 2024As Medicare open enrollment begins, the NCPA is urging CMS to facilitate appropriate PBM contracting for pharmacies in the upcoming plan year.
- Pharmacist-Led Interventions Improve Hypertension Outcomes in Remote Program September 5, 2024Findings were presented at the American Heart Association's Hypertension Scientific Sessions in Chicago, Illinois.
- C Difficile Treatment Shows Positive Results in Phase 2 Study September 5, 2024CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.
Pharmacy Times articles
- Tailoring CLL Treatment: Managing Toxicities and Comorbidities in Targeted Therapies September 7, 2024Alessandra Ferrajoli, MD, discusses the importance of renal function for BCL2 inhibitors to avoid tumor lysis syndrome and cardiovascular history for BTK inhibitors to mitigate arrhythmia risks.
- Study: Shingles Could Increase Risk of Cognitive Decline September 6, 2024Individuals with a history of shingles was significantly and independently connected with a 20% higher risk of for subjective cognitive decline.
- FDA Approves Sparsentan, With Data Indicating Slowing of Kidney Function Decline in IgA Nephropathy September 6, 2024Full traditional approval follows accelerated approval of the medication last year.
- Navigating Multiple Myeloma Care: Balancing CAR T-Cell Therapy and Immunotherapy September 6, 2024The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.
- NCPA Pushes CMS for Regulations Outlining PBM Contracting Guardrails September 6, 2024Agency must eliminate abuses by plans and PBMs in Part D, ensure patient access to accurate information.
- FDA Grants Breakthrough Therapy Designation to Sanbexin for Acute Ischemic Stroke September 6, 2024Edaravone and dexborneol sublingual tablets are an innovative first drug to be designed for treatment of stroke and granted this designation.
- RSV Vaccination Could Decrease Hospitalization Among Adults 60 Years and Older September 6, 2024RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.
- The Evolution and Clinical Applications of MRD Testing in Lymphoma September 6, 2024Reid Merryman, MD, discusses the potential for minimal residual disease (MRD) to inform treatment decisions, identify lymphoma subgroups, and infer gene expression.
- Disease- and Patient-Related Factors Guide Decisions For Patients With Myelofibrosis Receiving allo-HCT September 6, 2024Disease-related factors include several prognostic scoring systems, such as DIPSS, whereas patient-related factors involve age, comorbidities, spleen size, and anemia.
- What to Expect As New CMS Hospital Transparency Requirements Take Effect in 2025 September 6, 2024New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com